Cyclodextrin protects podocytes in diabetic kidney disease

Area of Science:

• Nephrology
• Endocrinology
• Metabolic Diseases

Background:

• Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease, often associated with cholesterol dysregulation.
• The ATP-binding cassette transporter ABCA1 plays a crucial role in cholesterol efflux, and its downregulation is implicated in DKD pathogenesis.

Purpose of the Study:

• To investigate the role of cholesterol metabolism and ABCA1 transporter in diabetic kidney disease.
• To evaluate the therapeutic potential of cyclodextrin (CD) in preserving podocyte function and improving metabolic control in experimental DKD.

Main Methods:

• Human podocytes and kidney biopsies were used to assess ABCA1 expression and cholesterol levels in DKD patients.
• In vitro studies exposed podocytes to patient sera, followed by treatment with cyclodextrin or simvastatin.
• Diabetic mice (BTBR ob/ob) received subcutaneous cyclodextrin, and outcomes including albuminuria, kidney parameters, and metabolic markers were evaluated.

Main Results:

• Human podocytes exposed to sera from diabetic patients with albuminuria showed increased cholesterol and decreased ABCA1 expression compared to those with normoalbuminuria.
• Glomerular ABCA1 downregulation was confirmed in early DKD patient biopsies.
• Cyclodextrin treatment, not simvastatin, protected podocytes in vitro and reduced albuminuria, mesangial expansion, and kidney cholesterol content in diabetic mice, alongside improved glycemic control and insulin release.

Conclusions:

• Impaired reverse cholesterol transport, characterized by ABCA1 downregulation, is a key feature of diabetic kidney disease.
• Cyclodextrin treatment demonstrates safety and efficacy in preserving podocyte function and ameliorating DKD in vitro and in vivo.
• Cyclodextrin therapy holds promise for improving both kidney function and metabolic control in diabetic patients.